Document:

exhibit1015

                 DNAPRINT/GENOMED CONTRACT GENOTYPING AGREEMENT

This Contract Genotyping Agreement (this "Agreement") is made and entered into
as of January 15, 2002 (the "Effective Date") by and between DNAprint genomics,
a Utah corporation, (hereinafter "DNAPRINT") and GenoMed LLC, a Delaware
corporation (hereinafter "GENOMED").

Recitals

DNAPRINT is the owner of certain genotyping equipment (a SNPstream 25K platform,
Beckman multi-mek and ancillary front end and back end equipment ), and desires
to provide identified genotyping services for GENOMED.

GENOMED is the owner of certain genotyping equipment (the UHT platform). GENOMED
is also the owner of certain DNA samples and related medical information
collected from patients with various diseases, and of certain rights therein.
GENOMED is in the business of disease research and product development, and
desires to contract the genotyping portion of the research with DNAPRINT.
GENOMED wishes to increase the genotyping throughput of DNAPRINTs laboratory so
that DNAPRINT can perform this work in a timely manner.

NOW, THEREFORE, in consideration of these premises, as well as the obligations
herein made and undertaken, the parties hereto do hereby agree as follows:

1. EQUIPMENT
        1.1. Placement. Subject to the terms and conditions of this Agreement, GENOMED
             will purchase from Orchid Biosciences (hereafter referred to as "ORCHID")
             and place at DNAPRINT a UHT genotyping platform system. On behalf of
             GENOMED, ORCHID will install and train DNAPRINT workers on the use of this
             equipment. In addition to this, GENOMED will purchase and place at DNAPRINT
             one or more thermal cyclers such that the number of amplifications that can
             be processed at once is at least 1,536. In addition, GENOMED will purchase
             and place one automated liquid handling system if determined by both
             parties that this item is necessary for DNAPRINT to execute under the terms
             of this Agreement. DNAPRINT will operate all equipment autonomously and the
             placed equipment shall remain at DNAPRINT for the duration of the
             agreement.
        1.2. Maintenance. DNAPRINT will assume financial responsibility for maintenance
             of the SNPstream 25K system. GENOMED will assume financial responsibility
             for maintenance of the UHT plate reader, UHT twister arm and, if placed,
             thermal.
        1.3. Operation. Only DNAPRINT employees or individuals approved by DNAPRINT may
             operate the equipment.
        1.4. Insurance. DNAPRINT is responsible for insuring the equipment against theft
             or destruction.
2. SERVICES
        2.1. Provision. DNAPRINT will provide GENOMED with at least 3 Million genotypes
             during the first year of this agreement. GENOMED will provide DNAPRINT with
             DNA specimens for genotyping. DNAPRINT will provide all necessary
             consumables, labor and non-UHT equipment for determining and transferring
             these genotypes.
        2.2. Payment. Subject to the terms and conditions of this agreement, and within
             30 days from DNAPRINTs request, but no more frequently than once per month,
             GENOMED will pay DNAPRINT a sum equal to 40 cents per determined and
             transferred genotype. In addition to this, if GENOMED realizes a net profit
             that exceeds $10,000,000 USD which was directly or indirectly enabled by
             compositions of matter produced under the terms of this Agreement, then
             GENOMED will provide DNAPRINT with a royalty of 5% on these realized net
             profits.
        2.3. Transfer. DNAPRINT will physically or electronically transfer genotyping
             data to GENOMED in a manner agreed upon by both parties.
3. SERVICES FOR THIRD PARTIES.
        3.1 Services. DNAPRINT may perform commercial genotyping operations for third
            parties, using GENOMED equipment, only with GENOMED approval. For third
            party contracts, DNAPRINT will provide all overhead, management and labor,

                                       1

            and DNAPRINT and GENOMED will share total net profits at a ratio of 3:1 to
            reflect their capital and physical contribution to such contracts.

4. CONTINUATION, TERM and TERMINATION.
        4.1. Services. The minimum term of the agreement is 2 years. After this minimum
             term, the Agreement shall continue indefinitely, but may be terminated by
             either party upon a material breach by the other, provided, however, that
             the breaching party has been given thirty (30) days to cure such breach.
             Sections 2.2 (Payment), 3.2 (Termination), 4 (Restrictions on Use), 5
             (Limited Warranty), 6 (Mediation and Arbitration), 7.5 (Assignment), 7.6
             (Governing Law), and 7.7 (Severability) shall survive expiration or early
             termination of this Agreement.
        4.2. Termination. Upon discontinuation of the agreement, GENOMED will satisfy
             any and all outstanding debts to DNAPRINT and DNAPRINT will return GENOMEDs
             equipment to GENOMED.
5. RESTRICTIONS ON USE
        5.1 DNAPRINT and GENOMED may sign subsequent to this Agreement, DNAPRINT agrees
            and understands that the genotyping data is the property of GENOMED, and
            that it acquires no rights therein and that it can use GENOMEDs Samples,
            including any Documentation, only for legitimate scientific research as
            directed by GENOMED, and for no other purpose whatsoever. DNAPRINT may not
            resell the Samples, or any portion thereof, for any reason.
        5.1 Privacy. Genotyping data is the property of GENOMED, and DNAPRINT may not
            sell, loan, disclose or present GENOMEDs data in any manner whatsoever,
            unless requested by or agreed to by GENOMED.
        5.2 Equipment. During the term of this Agreement, DNAPRINT is permitted to use
            GENOMED equipment for its own internal research and development. DNAPRINT
            is permitted to use GENOMED equipment for other contract genotyping
            customers only with GENOMED prior approval, and under the terms of this
            agreement.
6. Limited Warranty; Limitation of Liability
        6.1 Limited Warranty. DNAPRINT represents and warrents to GENOMED that DNAPRINT
            has the authority and licenses necessary to use its equipment for the
            purpose of contract genotyping. DNAPRINT also warrants the quality of the
            genotyping data delivered to GENOMED. GENOMEDS sole and exclusive remedy
            for DNAPRINTs breach of this limited warranty shall be a refund of the
            Payment. DNAPRINT disclaims all other warranties, express or implied, with
            regard to the data, including all implied warranties of merchantablity,
            fitness for a particular purpose, title, and non-infringement.
        6.2 Limitation on Liability. Neither party shall be liable to the other for any
            indirect, consequential, special or incidental damages (including damages
            for loss of business profits, business interruption, loss of business
            information, and the like) arising out of this Agreement even if such party
            has been advised of the possibility of such damages.
7. Mediation and Arbitration
        7.1 Mediation and arbitration approach. The parties agree to select a mutually
            agreeable, neutral third party to help them mediate any dispute that arises
            under the terms of this Agreement. Costs and fees associated with the
            mediation will be shared equally by the parties.
        7.2 Arbitration. If the mediation is unsuccessful, the parties agree that the
            dispute will be decided by binding arbitration under the rules of the
            American Arbitration Association. The decision of the arbitrators will be
            final and binding on the parties and may be entered and enforced in any
            court of competent jurisdiction by either party. The prevailing party in
            the arbitration proceedings will be awarded reasonable attorney fees,
            expert witness costs and expenses, and all other reasonable costs and
            expenses incurred in connection with the proceedings, unless the
            arbitrators for good cause determine otherwise.
8. General
        8.1 Notices. Any notice required or permitted hereunder must be in writing, and
            will be effective on the date of delivery when delivered personally, the
            next business day after dispatch when sent by Federal Express or other
            recognized overnight courier service, or the fifth business day after
            dispatch when sent by certified mail, postage prepaid, return receipt
            requested. Notices should be addressed to the other party at the address
            shown below or at such other address as a party may designate by ten days'
            advance written notice to the other party:

         DNAPRINT GENOMICS, INC.                     GENOMED INC.
         900 Cocoanut, Ave.                          4560 Clayton Ave.
         Sarasota, FL 34236                          St. Louis, MO 63110

        8.2 Entire Agreement; Modifications. This Agreement constitutes the entire
            agreement of the parties with respect to the subject matter hereof and
            supersedes all prior representations, proposals, discussions, and
            communications, whether oral or in writing. This Agreement may be modified
            or amended only by a writing executed by a duly authorized representative
            of each party.
        8.3 Force Majeure. Neither party will be liable to the other for any failure or
            delay caused by events beyond such party's control, including, without
            limitation, sabotage, terrorism, riots, insurrections, fires, flood, storm,
            explosions, war or earthquakes. However, if such events have a material
            impact on the satisfaction of this Agreement, and shall continue for thirty
            (30) days or more, the other party shall have the option of terminating
            this Agreement by giving written notice of termination.
        8.4 Change in Law; Change in Circumstances. No party shall make or receive any
            payment or take any action under this Agreement if any judicial decision,
            legislative action, or regulatory or other administrative interpretation,
            whether federal or state, would render illegal the conduct of either party
            under this Agreement. If performance by either party of any term of this
            Agreement should be deemed illegal by any party or third party who is
            essential to performance of this Agreement for any such reason, either
            party shall have the right to require that the other party renegotiate the
            terms of this Agreement.
        8.5 Assignment. This Agreement will be binding upon and inure to the benefit of
            the parties hereto, their successors and permitted assigns. Either party
            may assign this Agreement in its entirety to a successor corporation upon
            notice to the other party in the event of a merger or an acquisition of all
            or substantially all of the assets of the assigning party. This agreement
            between DNAPRINT and GENOMED will survive and insure to the benefit of the
            other party through any and all mergers, acquisitions, or change in
            ownership.
        8.6 Governing Law. All questions concerning the validity, operation,
            interpretation, and construction of this Agreement will be governed by and
            determined in accordance with the laws of the State of California, without
            regard to its conflict of laws provisions. Application of the United
            Nations Convention on Contracts for the International Sale of Goods is
            specifically excluded.
        8.7 Severability. If a court of competent jurisdiction determines that any
            provision of this Agreement is invalid, illegal, or otherwise
            unenforceable, such provision shall be replaced with a valid, enforceable
            provision as nearly as possible in accordance with the stated intention of
            the paties, while the remainder of this Agreement shall remain in full
            force and effect. To the extent any provision cannot be enforced in
            accordance with the stated intentions of the parties, such provision shall
            be deemed not to be a part of this Agreement.
        8.8 Counterparts. This agreement may be executed in any number of counterparts,
            all of which together will constitute one and the same instrument.

IN WITNESS THEREOF, the parties have caused this Agreement to be executed by
their respective duly authorized representatives as set forth below:

DNAPRINT GENOMICS                           GENOMED

By:/s/ Tony Frudakis                        By:/s/ Jerry E. White
Tony Frudakis, Ph.D.                           Jerry E. White
CEO                                            President and CEOexhibit1016

                                FUNDING AGREEMENT

        THIS FUNDING AGREEMENT made this 25th day of February, 2002 by and among
DNAPRINT GENOMICS, INC., a corporation organized under the laws of the state of
Utah (the "Company"), TONY FRUDAKIS, a citizen of the state of Florida ("T.
Frudakis"), GEORGE FRUDAKIS, a citizen of the state of Florida ("G. Frudakis"),
CARL SMITH III, a citizen of the state of Florida ("Smith") and RICHARD CRAIG
HALL, a citizen of the state of Florida ("Hall" and collectively with T.
Frudakis, G. Frudakis and Smith "Lenders" or each individually an "Lender").

                                    RECITALS

        WHEREAS, the Company desires to secure a loan of Two Million Dollars
($2,000,000) to be funded over the course of a ten (10) month period commencing
March 1, 2002 (the "Term"); and

        WHEREAS, the Lenders desire to provide such funding as a loan; and

        WHEREAS, as a condition of their agreement to provide such funding, the
three Lenders who are not directors or officers of the Company require at least
one officer to participate as a Lender hereunder; and

        WHEREAS, the inclusion of Dr. Frudakis as a Lender satisfies this requirement.

        NOW THEREFORE, the parties agree as follows:

        1. Funding. Each Lender agrees to provide a loan of not less than Five
Hundred Thousand Dollars ($500,000) to the Company in equal quarterly
installments of $125,000, payable on March 31, 2002, June 30, 2002, September
30, 2002 and December 31, 2002 (each a "Funding Date").

        2. Consideration. In consideration for the loans set forth above, the
Company shall repay the principal together with simple interest at a rate of 8%
per annum. This loan will be repaid in full to the Lenders on January 31, 200__.
If for any reason the Company shall fail to repay the loan at maturity, the sole
remedy of the Lenders shall be the issuance by the Company of shares of its
restricted common stock. The number of shares to be issued will be calculated
using the then-current principal balance, together with accrued but unpaid
interest, and a share price of $0.035 per share.

        3. Joint and Several Liability. The liability of the Lenders to the Company
to make the required loans shall be joint and several. Thus, if in any quarter
during the Term one or more of the Lenders defaults in his obligation to make
his required loan, the remaining non-defaulting Lenders, within five (5)
business days of receipt of written notice from the Company of such default,
shall each contribute to the Company his pro rata share of the loan amounts in
default.

                                       1

        4. Indemnification. Each Lender who defaults in his obligations hereunder
agrees to protect, indemnify and hold each of the other Lenders harmless from
and against all damages, losses, claims, cost, expenses or actions arising from
said Lender's default.

        5. Miscellaneous.

           a. Notices. All notices and other communications given or made pursuant
hereto shall be in writing and shall be deemed to have been duly given or made
as of the date delivered, mailed or transmitted, and shall be effective upon
actual receipt, if delivered personally or by courier, mailed by registered or
certified mail (postage prepaid, return receipt requested) to the parties at the
following addresses (or at such other address for a party as shall be specified
by like changes of address) or sent by electronic transmission to the facsimile
number specified below:

         If to Company:

                  DNAPrint genomics, Inc.
                  900 Cocoanut Avenue
                  Sarasota, Florida 34236
                  Attention:  Tony Frudakis

         If to Smith:

                  1819 Main Street, Suite 602
                  Sarasota, Florida 34236

         If to Hall:

                  1819 Main Street, Suite 602
                  Sarasota, Florida 34236

         If to T. Frudakis:

                  900 Cocoanut Avenue
                  Sarasota, Florida 34236

         If to G. Frudakis:

                  900 Cocoanut Avenue
                  Sarasota, Florida 34236

or to such other address as any party may have furnished in writing the other
parties in the manner provided above.

        b. Parties Bound. The provisions of this Agreement shall apply to, inure to
the benefit of, and be binding upon the parties hereto and their respective
heirs, successors, assigns, administrators, executors. In no event may any party

                                       2

assign any of its rights, privileges, duties, or obligations hereunder. Any
assignment in violation of the foregoing shall be null and void.

        c. Multiple Counterparts. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original and all of which shall
be deemed collectively one agreement, but, in making proof hereof, it shall
never be necessary to exhibit more than one such counterpart.

        d. Entire Agreement: Modifications. This Agreement constitutes the final,
exclusive, and complete understanding of the parties with respect to the subject
matter hereof and supersedes any and all prior agreements, understandings and
discussions with respect thereto.

        e. Captions. The captions in this Agreement are for convenience only and
shall not be considered a part of or affect the construction or interpretation
of any provision of this Agreement.

        f. Governing Law. This Agreement shall be governed by and enforceable
under, and construed in accordance with, the laws of Florida, regardless of the
laws that might otherwise govern under applicable principles of conflicts of
law.

        g. Third Party Beneficiaries. No individual, firm, corporation,
partnership, or other entity shall be a third-party beneficiary of this
Agreement.

        h. Remedies Cumulative. Except for the remedy limitation set forth in
Section 2 hereof, the remedies of the parties under this Agreement are
cumulative and will not exclude any other remedies to which any party may be
lawfully entitled.

        i. Severability. If any provision of this Agreement is held to be illegal,
invalid, or unenforceable under present or future laws effective during the term
hereof, such provision shall be fully severable and this Agreement shall be
construed and enforced as if such illegal, invalid, or unenforceable provision
never comprised a part hereof; and the remaining provisions hereof shall remain
in full force and effect and shall not be affected by such illegal, invalid, or
unenforceable provision or by its severance herefrom. Furthermore, in lieu of
such illegal, invalid, or an enforceable provision, there shall be added
automatically as part of this Agreement a provision as similar in its terms to
such illegal, invalid, or unenforceable provision as may be possible and be
legal, valid, and enforceable.

                         [Signatures on following page.]

                                       3

        IN WITNESS WHEREOF, the parties have executed this Funding Agreement on the
date set forth above.

                                           DNAPRINT GENOMICS, INC.

                                           By:/s/ Tony Frudakis
                                              Tony Frudakis
                                              As its President

                                           LENDERS

                                           /s/ Tony Frudakis
                                           Tony Frudakis

                                           /s/ George Frudakis
                                           George Frudakis

                                           /s/ Carl Smith III
                                           Carl Smith III

                                           /s/ Richard Craig Hall
                                           Richard Craig Hall

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]